Pedersen C, Lundgren J D, Nielsen T, Andersen W H
Department of Infectious Diseases, Hvidovre Hospital, University of Copenhagen, Denmark.
Scand J Infect Dis. 1989;21(4):375-80. doi: 10.3109/00365548909167440.
A total of 100 consecutive patients with AIDS were evaluated for efficacy and safety of treatment and secondary prophylaxis directed against Pneumocystis carinii pneumonia (PCP). 89 episodes of PCP were recorded in 75 patients. 63 of the 75 patients (84%) with a first episode of PCP were discharged. Of 72 patients with a first episode of PCP who were initially treated with trimethoprim-sulfamethoxazole. 76% completed therapy successfully. Side effects were common, but generally mild and tolerated during continued treatment. 7/11 patients (64%) with a first episode of PCP who required mechanical ventilation were discharged. Long term prognosis for these patients was not worse than for patients who did not require mechanical ventilation. Relapse of PCP occurred in 3/50 patients (6%) during secondary prophylaxis, 160 mg trimethoprim and 800 mg sulfamethoxazole (TMP-SMZ) every 24 h, compared to 11/16 (69%) patients who were not receiving prophylaxis (p less than 0.00001). No patients discontinued prophylaxis because of side effects. It is concluded that for most patients with AIDS and PCP, treatment and secondary prophylaxis with TMP-SMZ is safe and effective.
共对100例连续的艾滋病患者进行了针对卡氏肺孢子虫肺炎(PCP)的治疗及二级预防的疗效和安全性评估。75例患者记录到89次PCP发作。75例首次发作PCP的患者中有63例(84%)出院。72例首次发作PCP且最初接受甲氧苄啶-磺胺甲恶唑治疗的患者中,76%成功完成治疗。副作用很常见,但通常较轻,在持续治疗期间可耐受。11例首次发作PCP且需要机械通气的患者中有7例(64%)出院。这些患者的长期预后并不比不需要机械通气的患者差。在二级预防期间,每24小时服用160毫克甲氧苄啶和800毫克磺胺甲恶唑(TMP-SMZ),50例患者中有3例(6%)发生PCP复发,相比之下,未接受预防的16例患者中有11例(69%)复发(p小于0.00001)。没有患者因副作用而停止预防。结论是,对于大多数艾滋病合并PCP患者,TMP-SMZ治疗及二级预防是安全有效的。